An analysis of data collected on thousands of ovarian cancer patients in California turned up some promising news for women with this diagnosis. While the study, conducted by researchers at UC Davis, confirmed earlier findings on characteristics associated with ovarian cancer survival — younger age, earlier stage and lower grade tumors at diagnosis — it also identified a surprising number of long-term survivors who didn’t meet those criteria.
“The perception that almost all women will die of this disease is not correct,” says Rosemary Cress, lead author of the study, published online August 5, 2015 in the Journal of Obstetrics and Gynecology. “This information will be helpful to physicians who first diagnose these patients and the obstetricians/gynecologists who take care of them after they receive treatment from specialists.”
Cress, an epidemiologist and associate adjunct professor in the UC Davis Department of Public Health Sciences, used the California Cancer Registry to analyze data reported on all California residents diagnosed with epithelial ovarian cancer between 1994 and 2001. Epithelial ovarian cancer is the most common type of ovarian cancer, occurring in nine out of 10 cases.
Of the 11,541 patients in the registry database, 3,582 (31 percent) survived more than 10 years, Cress and her colleagues discovered. It was the first time that research has looked at 10-year trajectories for patients; most survival studies have looked only at 5-year survival or less. What struck the researchers was that of the long-term survivors, 954 of them had been considered to be at high risk of dying from their disease, either because of their tumor stage, grade or older age at diagnosis.
“This information is important for patient counseling,” says study co-author Gary Leiserowitz, a professor of gynecologic oncology and interim chair of the UC Davis Department of Obstetrics and Gynecology. “Many patients and physicians know that ovarian cancer is a dangerous cancer, but they don’t realize that there is significant biological variability among patients. It’s not a uniformly fatal prognosis.”
One such survivor is Jacqueline Price, 74. The Fair Oaks, Calif. woman was diagnosed at age 60 with stage IIIC ovarian cancer. Determined to make the right decision about how to proceed, she asked the doctor for the pathology report.
“It said I had two months and to call hospice,” says Price. “I thought, if I only have a couple of months, I want to spend it with my family. I wasn’t going to have any treatment. It was doom and gloom.”
Leiserowitz, her oncologist, urged Price to reconsider. When the “fog cleared,” Price recalls, she opted to go ahead with the surgery, and soon afterward agreed to aggressive chemotherapy treatment.
“I cannot even imagine missing these past 15 years,” Price says now. Her experience spurred her to reach out to other ovarian cancer patients and survivors as an advocate and “healing circle” organizer. She says findings from the UC Davis study will help women understand that ovarian cancer is not an automatic death sentence, she says, and empower them to remain optimistic, which in and of itself can benefit survivorship.
New, effective treatments and clinical trials coming out all the time.
I'm at seven years, and know women who have done longer times.
Keep the Faith, Keep the Hope and thanks to all the researchers and oncologists for their marvelous inroads.
Do some research and check low-does maintenance regimens of Metformin, COX-2 inhibitors, and non-specific Beta Blockers with your doctor (all standard available medications). If they would be completely safe for you, they could be considered for a maintenance regimen as there is some evidence they may help impede the cancer from spreading and growing. I could probably dig up article references if you are interested.
All the best,
Page 1 of 1 1
You must log in to use this feature, please click here to login.